We are live on ! Find out more
IART icon

Integra LifeSciences

16.85 USD
-0.03
0.18%
At close Updated Aug 27, 4:00 PM EDT
Pre-market
After hours
16.85
0.00
0%
1 day
-0.18%
5 days
0.24%
1 month
-13.72%
3 months
10.93%
6 months
48.07%
Year to date
40.3%
1 year
13.32%
5 years
-76.93%
10 years
-60.94%
 

About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

Employees: 4,427

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 66.7%
Neutral 30.3%
Negative 3%
Positive
Zacks Investment Research
21 hours ago
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
7 days ago
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Positive
Zacks Investment Research
8 days ago
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Positive
Zacks Investment Research
22 days ago
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Neutral
Seeking Alpha
29 days ago
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
Positive
Zacks Investment Research
29 days ago
3 Stocks Showing Breakout Potential Ahead of August
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.
3 Stocks Showing Breakout Potential Ahead of August
Neutral
Zacks Investment Research
29 days ago
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
MarketBeat
29 days ago
Integra LifeSciences Q2 Earnings Call Highlights
Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.
Integra LifeSciences Q2 Earnings Call Highlights
Positive
Zacks Investment Research
29 days ago
Integra LifeSciences (IART) Q2 Earnings Top Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.
Integra LifeSciences (IART) Q2 Earnings Top Estimates
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
Integra LifeSciences Reports Second Quarter 2026 Financial Results
Price charts implemented using Lightweight Charts™